Mosnodenvir

Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates[1][2].

Product Specifications

CAS Number

[2890688-86-3]

Product Name Alternative

JNJ-1802

UNSPSC

12352005

Target

Dengue Virus; Flavivirus; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/mosnodenvir.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CS(C1=CC(OC)=CC(N[C@@H](C2=C(C=C(C=C2)Cl)OC)C(C(C3=C4)=CNC3=CC=C4OC(F)(F)F)=O)=C1)(=O)=O

Molecular Formula

C26H22ClF3N2O6S

Molecular Weight

582.98

References & Citations

[1]Ackaert O, et al. Safety, tolerability and pharmacokinetics of JNJ-1802, a pan-serotype dengue direct antiviral small molecule, in a Phase 1, double-blind, randomized, dose-escalation study in healthy volunteers. Clin Infect Dis. 2023 May 10:ciad284.|[2]Goethals O, et al. Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates. Nature. 2023 Mar;615 (7953) :678-686.|[3]McCormack CP, et al. Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics. PLoS Comput Biol. 2023 Dec 6;19 (12) :e1011662.